

Validation data for Anti-hBCMA-βGal

<https://www.invivogen.com/anti-human-bcma-bgal>

For research use only

Version 24D17-AK

Anti-hBCMA-βGal is a bispecific antibody that binds to two sites: human B cell maturation antigen (hBCMA) and *E. coli* beta-galactosidase (β-Gal). It is used as a negative control for Anti-hBCMA-CD3 bispecific antibody that, like paicanalotamab, engages unstimulated T cells to proliferate and exert cytotoxic activity on BCMA-positive myeloma cells. The inability of Anti-hBCMA-βGal to activate T cells in the presence of B cells has been validated using InvivoGen's Jurkat-Lucia™ NFAT cells, a human T cell reporter cell line that stably expresses an NFAT-inducible Lucia luciferase reporter gene, and the human Raji B lymphoma cell line stably overexpressing hBCMA on their surface (Figure 1). Anti-hBCMA-CD3 served as a positive control.

Evaluation of T cell activation




Figure 1: Dose-dependent activation of Jurkat-Lucia™ NFAT cells with Anti-hBCMA-CD3 in the presence of Raji cells expressing hBCMA. Raji cells, expressing hBCMA were pre-incubated with increasing concentrations of Anti-hBCMA-CD3 or Anti-hBCMA-βGal (negative control) for 30 minutes before addition of Jurkat-Lucia™ NFAT cells. After 24 hours incubation, T cell activation was determined by measuring the Lucia luciferase activity using QUANTI-Luc™ detection reagent. Results are presented as fold change over non-induced cells (mean ± SEM).

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Asia: +852 3-622-3480

E-mail: info@invivogen.com